Paradigm Biocapital Advisors LP Sells 1,075,610 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Paradigm Biocapital Advisors LP trimmed its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 37.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,820,079 shares of the company's stock after selling 1,075,610 shares during the period. Viridian Therapeutics comprises approximately 1.2% of Paradigm Biocapital Advisors LP's investment portfolio, making the stock its 21st biggest position. Paradigm Biocapital Advisors LP owned approximately 2.30% of Viridian Therapeutics worth $34,891,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Parkman Healthcare Partners LLC increased its holdings in Viridian Therapeutics by 155.9% in the fourth quarter. Parkman Healthcare Partners LLC now owns 1,087,634 shares of the company's stock valued at $20,850,000 after purchasing an additional 662,634 shares during the period. Nuveen Asset Management LLC grew its holdings in Viridian Therapeutics by 198.2% during the 4th quarter. Nuveen Asset Management LLC now owns 681,012 shares of the company's stock worth $13,055,000 after acquiring an additional 452,627 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Viridian Therapeutics during the 4th quarter worth about $855,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Viridian Therapeutics by 40.7% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,400 shares of the company's stock worth $930,000 after acquiring an additional 13,990 shares during the period. Finally, D. E. Shaw & Co. Inc. grew its holdings in Viridian Therapeutics by 220.2% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 442,070 shares of the company's stock worth $8,474,000 after acquiring an additional 304,003 shares during the period.

Viridian Therapeutics Stock Up 2.5%

Shares of VRDN stock traded up $0.32 on Friday, reaching $12.94. 597,678 shares of the company were exchanged, compared to its average volume of 1,195,473. The company has a market cap of $1.06 billion, a price-to-earnings ratio of -3.00 and a beta of 0.57. The company has a 50-day moving average of $13.41 and a 200-day moving average of $17.17. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. Viridian Therapeutics, Inc. has a one year low of $9.90 and a one year high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.87) EPS for the quarter, topping analysts' consensus estimates of ($0.95) by $0.08. The firm had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.16 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The firm's quarterly revenue was up .0% compared to the same quarter last year. Analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on VRDN shares. The Goldman Sachs Group decreased their price target on Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. HC Wainwright reiterated a "buy" rating and set a $34.00 price target on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. Royal Bank of Canada cut their price objective on shares of Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. JMP Securities cut their price objective on shares of Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating on the stock in a research report on Wednesday, May 7th. Finally, Needham & Company LLC cut their price objective on shares of Viridian Therapeutics from $38.00 to $36.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $36.70.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.